Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of SBRT followed by apatinib in advanced liver cancer
ChiCTR1800014313Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in liver cancer and hepatocellular carcinoma (HCC) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: Time to progression and Overall survival. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
liver cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800014313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014313.